MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- IPCA LABS - ADCOCK INGRAM (S. Africa)
IPCA LABS vs ADCOCK INGRAM (S. Africa) - Comparison Results
IPCA LABS Change
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 IPCA LABS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-19 |
ADCOCK INGRAM Jun-14 |
IPCA LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,042 | 373 | - | |
| Low | Rs | 590 | 269 | - | |
| Sales per share (Unadj.) | Rs | 298.6 | 111.1 | - | |
| Earnings per share (Unadj.) | Rs | 35.0 | -28.0 | - | |
| Cash flow per share (Unadj.) | Rs | 49.4 | -23.2 | - | |
| Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 247.1 | 87.2 | - | |
| Shares outstanding (eoy) | m | 126.35 | 168.78 | - | |
| Bonus/Rights/Conversions | ESOS | - | - | ||
| Price / Sales ratio | x | 2.7 | 2.9 | 94.4% | |
| Avg P/E ratio | x | 23.3 | -11.5 | -203.1% | |
| P/CF ratio (eoy) | x | 16.5 | -13.9 | -119.1% | |
| Price / Book Value ratio | x | 3.3 | 3.7 | 89.6% | |
| Dividend payout | % | 8.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 103,108 | 54,239 | 190.1% | |
| No. of employees | `000 | 13.4 | 4.3 | 313.1% | |
| Total wages/salary | Rs m | 7,874 | 3,404 | 231.3% | |
| Avg. sales/employee | Rs Th | 2,807.0 | 4,366.6 | 64.3% | |
| Avg. wages/employee | Rs Th | 585.8 | 793.0 | 73.9% | |
| Avg. net profit/employee | Rs Th | 329.0 | -1,100.3 | -29.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 37,732 | 18,746 | 201.3% | |
| Other income | Rs m | 577 | 131 | 439.4% | |
| Total revenues | Rs m | 38,309 | 18,877 | 202.9% | |
| Gross profit | Rs m | 6,901 | -3,249 | -212.4% | |
| Depreciation | Rs m | 1,824 | 809 | 225.5% | |
| Interest | Rs m | 189 | 508 | 37.2% | |
| Profit before tax | Rs m | 5,465 | -4,434 | -123.2% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,042 | 277 | 376.2% | |
| Profit after tax | Rs m | 4,422 | -4,724 | -93.6% | |
| Gross profit margin | % | 18.3 | -17.3 | -105.5% | |
| Effective tax rate | % | 19.1 | -6.2 | -305.3% | |
| Net profit margin | % | 11.7 | -25.2 | -46.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,778 | 13,730 | 173.2% | |
| Current liabilities | Rs m | 10,975 | 7,725 | 142.1% | |
| Net working cap to sales | % | 33.9 | 32.0 | 105.9% | |
| Current ratio | x | 2.2 | 1.8 | 121.9% | |
| Inventory Days | Days | 104 | 111 | 93.5% | |
| Debtors Days | Days | 66 | 124 | 53.2% | |
| Net fixed assets | Rs m | 20,368 | 8,003 | 254.5% | |
| Share capital | Rs m | 253 | 87 | 290.3% | |
| Net worth | Rs m | 31,224 | 14,714 | 212.2% | |
| Long term debt | Rs m | 1,409 | 5,171 | 27.2% | |
| Total assets | Rs m | 45,507 | 27,795 | 163.7% | |
| Interest coverage | x | 30.0 | -7.7 | -387.5% | |
| Debt to equity ratio | x | 0 | 0.4 | 12.8% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 122.9% | |
| Return on assets | % | 10.1 | -15.2 | -66.8% | |
| Return on equity | % | 14.2 | -32.1 | -44.1% | |
| Return on capital | % | 17.3 | -19.8 | -87.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,923 | 1,600 | 307.7% | |
| From Investments | Rs m | -1,563 | -491 | 318.1% | |
| From Financial Activity | Rs m | -1,832 | 4,693 | -39.0% | |
| Net Cashflow | Rs m | 1,528 | 5,801 | 26.3% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.15 Rs / ZAR
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare IPCA LABS With: STRIDES PHARMA SCIENCE LUPIN FDC NOVARTIS SUVEN LIFE SCIENCES
Today's Market
Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)
Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.
Related Views On News
IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)
Sep 29, 2020 | Updated on Sep 29, 2020For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
If the Market Falls, I Will Do This... (Fast Profits Daily)
Apr 1, 2021What should you do if the market falls? In this video, I'll tell you what I will do.
The Indian Real Estate Party Has Just Begun (Profit Hunter)
Apr 1, 2021A favourable demand supply scenario makes a strong case for real estate prices.
The Dilemma of Investing in Bharti Airtel 
(Views On News)
Apr 1, 2021
Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market
More
